As of 10:30 AM on the 6th, Pamisell is trading at 23,250 KRW, up 2.42% from the previous day. This represents a 23.34% increase compared to July 9. Pamisell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.
Today, foreigners are tentatively recorded as net buyers of 102,014 shares. Over the past five days, individual investors have net sold 314,101 shares, while foreigners and institutions have net bought 256,517 shares and 20,008 shares, respectively.
On July 28, Pamisell was a market topic with the news of Moderna's Phase 3 clinical trial.

[Table] Foreigners and Institutions Net Trading Volume (Unit: shares)

※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
